Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101150
Song Li MD , Yiwu Zheng PhD , Lei Cheng MD, PhD
Messenger RNA (mRNA) vaccines are composed of mRNA sequences encoding pathogens. The first coronavirus mRNA vaccine (BNT162B2, Pfizer/BioNTech), approved in the United Kingdom in 2020, had prevented approximately 20 million deaths globally within the first year of use. mRNA vaccines were initially used against tumors and infectious diseases, but recent research has also turned its attention to the prevention of allergic diseases. Here, we summarized the characteristics and outcomes of mRNA vaccines in preventing allergic diseases and analyzed their advantages over traditional inactivated vaccines and DNA vaccines. This review focused on the feasibility, potential mechanisms, and preclinical research results of prophylactic allergen mRNA vaccines in the prevention of type I hypersensitivity reactions, and preliminarily addressed the key issues in clinical trials of allergen mRNA vaccines. Allergen mRNA vaccines hold promise for preventing IgE-mediated allergic diseases, yet their potential uses warrant further clinical investigations.
{"title":"Messenger RNA vaccines in the prevention of allergic diseases","authors":"Song Li MD , Yiwu Zheng PhD , Lei Cheng MD, PhD","doi":"10.1016/j.waojou.2025.101150","DOIUrl":"10.1016/j.waojou.2025.101150","url":null,"abstract":"<div><div>Messenger RNA (mRNA) vaccines are composed of mRNA sequences encoding pathogens. The first coronavirus mRNA vaccine (BNT162B2, Pfizer/BioNTech), approved in the United Kingdom in 2020, had prevented approximately 20 million deaths globally within the first year of use. mRNA vaccines were initially used against tumors and infectious diseases, but recent research has also turned its attention to the prevention of allergic diseases. Here, we summarized the characteristics and outcomes of mRNA vaccines in preventing allergic diseases and analyzed their advantages over traditional inactivated vaccines and DNA vaccines. This review focused on the feasibility, potential mechanisms, and preclinical research results of prophylactic allergen mRNA vaccines in the prevention of type I hypersensitivity reactions, and preliminarily addressed the key issues in clinical trials of allergen mRNA vaccines. Allergen mRNA vaccines hold promise for preventing IgE-mediated allergic diseases, yet their potential uses warrant further clinical investigations.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101150"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101155
Freda Yang MBChB MD(Res) , Justin D. Salciccioli MBBS MA , Rhea E. Patel BSc , Marcus McClean MBChB , Chloe I. Bloom MBBS PhD
Background
Biologic therapies improve outcomes in severe asthma, but eligibility criteria vary globally, influencing the proportion of patients who qualify. We systematically reviewed studies to estimate the global prevalence of biologic eligibility in patients aged ≥12 years with American Thoracic Society / European Respiratory Society (ATS/ERS)-defined severe asthma and the proportion eligible for each biologic.
Methods
Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Two reviewers independently screened studies, extracted data on eligibility proportions and criteria, and assessed quality using the AXIS tool.
Results
Ten observational studies, including 3500 patients with ATS/ERS-defined severe asthma, met the inclusion criteria. Across all studies, 1770 patients (51%) were eligible for at least 1 biologic, though estimates ranged widely from 24% to 91%, largely reflecting differences in national eligibility criteria. Omalizumab eligibility was reported in 8 studies (16%, range 6%–66%), mepolizumab in 9 studies (27%, 19%–78%), benralizumab in 6 studies (25%, 19%–53%), reslizumab in 6 studies (17%, 6%–41%), and dupilumab in 2 studies (41%, 37%–75%). No study assessed tezepelumab. Overall, the lowest eligibility (24%) was reported in the European IDEAL cohort due to stringent exacerbation and biomarker criteria, whereas the highest (91%) was observed in a Canadian single-centre cohort using less restrictive national regulatory criteria.
Conclusion
Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited.
{"title":"Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review","authors":"Freda Yang MBChB MD(Res) , Justin D. Salciccioli MBBS MA , Rhea E. Patel BSc , Marcus McClean MBChB , Chloe I. Bloom MBBS PhD","doi":"10.1016/j.waojou.2025.101155","DOIUrl":"10.1016/j.waojou.2025.101155","url":null,"abstract":"<div><h3>Background</h3><div>Biologic therapies improve outcomes in severe asthma, but eligibility criteria vary globally, influencing the proportion of patients who qualify. We systematically reviewed studies to estimate the global prevalence of biologic eligibility in patients aged ≥12 years with American Thoracic Society / European Respiratory Society (ATS/ERS)-defined severe asthma and the proportion eligible for each biologic.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Two reviewers independently screened studies, extracted data on eligibility proportions and criteria, and assessed quality using the AXIS tool.</div></div><div><h3>Results</h3><div>Ten observational studies, including 3500 patients with ATS/ERS-defined severe asthma, met the inclusion criteria. Across all studies, 1770 patients (51%) were eligible for at least 1 biologic, though estimates ranged widely from 24% to 91%, largely reflecting differences in national eligibility criteria. Omalizumab eligibility was reported in 8 studies (16%, range 6%–66%), mepolizumab in 9 studies (27%, 19%–78%), benralizumab in 6 studies (25%, 19%–53%), reslizumab in 6 studies (17%, 6%–41%), and dupilumab in 2 studies (41%, 37%–75%). No study assessed tezepelumab. Overall, the lowest eligibility (24%) was reported in the European IDEAL cohort due to stringent exacerbation and biomarker criteria, whereas the highest (91%) was observed in a Canadian single-centre cohort using less restrictive national regulatory criteria.</div></div><div><h3>Conclusion</h3><div>Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101155"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101133
Olga Patricia Monge Ortega MD, MSc , Ignacio Rivero Gairaud MD , Giovanni Sedó Mejía MD
Background
Epidemiological data on allergen sensitisation in Costa Rica are limited, while prevalence of allergic diseases in the world is rising. This study aims to determine the epidemiology and patterns of allergen sensitisation in patients who underwent prick testing.
Methods
A retrospective descriptive-observational study was conducted, including 1001 patients aged >12 years undergoing prick testing between 2019 and 2021. Descriptive statistics were used to collect data on demographics, aeroallergens and food sensitisation.
Results
The study population had a mean age of 35.9 ± 16.3 years and was predominantly female. Most patients were from San José, with chronic rhinitis being the most common pre-test diagnosis. Mites (Dermatophagoides farinae, Dermatophagoides pteronissinus), feline epithelium and cockroach mixture were the most common aeroallergens, while shrimp and shellfish were the main food allergens. A significant increase in sensitisation was observed in patients with pre-existing allergic conditions.
Conclusion
The results underline the high prevalence of allergen sensitisation in patients with allergic diseases in Costa Rica, especially in urban areas, and highlight the importance of allergen identification for effective management and prevention.
{"title":"Epidemiology and allergen sensitisation in patients undergoing prick testing","authors":"Olga Patricia Monge Ortega MD, MSc , Ignacio Rivero Gairaud MD , Giovanni Sedó Mejía MD","doi":"10.1016/j.waojou.2025.101133","DOIUrl":"10.1016/j.waojou.2025.101133","url":null,"abstract":"<div><h3>Background</h3><div>Epidemiological data on allergen sensitisation in Costa Rica are limited, while prevalence of allergic diseases in the world is rising. This study aims to determine the epidemiology and patterns of allergen sensitisation in patients who underwent prick testing.</div></div><div><h3>Methods</h3><div>A retrospective descriptive-observational study was conducted, including 1001 patients aged >12 years undergoing prick testing between 2019 and 2021. Descriptive statistics were used to collect data on demographics, aeroallergens and food sensitisation.</div></div><div><h3>Results</h3><div>The study population had a mean age of 35.9 ± 16.3 years and was predominantly female. Most patients were from San José, with chronic rhinitis being the most common pre-test diagnosis. Mites (<em>Dermatophagoides farinae</em>, <em>Dermatophagoides pteronissinus</em>), feline epithelium and cockroach mixture were the most common aeroallergens, while shrimp and shellfish were the main food allergens. A significant increase in sensitisation was observed in patients with pre-existing allergic conditions.</div></div><div><h3>Conclusion</h3><div>The results underline the high prevalence of allergen sensitisation in patients with allergic diseases in Costa Rica, especially in urban areas, and highlight the importance of allergen identification for effective management and prevention.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101133"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101154
Sven Becker MD , Martin Feindor MD , Anke Graessel PhD , Isabel Fernández de Alba MD , Katrin Birkholz PhD , Jennifer Raab PhD , Filippo Fassio MD , Dolores Hernandez MD , Neil Valentine Mr. , Robin Abro Mr. , Oliver Fuchs MD , Simon Blank PhD , Markus Ollert MD , David Gonzalez-de-Olano MD , Ludger Klimek MD , Erika Jensen-Jarolim MD , Peter Schmid-Grendelmeier MD , Gerald Hofer PhD , Matthias F. Kramer MD
Background
Allergen Immunotherapy (AIT) is an effective treatment for patients with pollen, house dust mite, or venom allergy, but treatment adherence can be challenging. Patient preferences play a crucial role in acceptance and adherence to AIT, but little is known about these preferences. This study aimed to understand patient preferences for AIT and how these preferences influence treatment acceptance.
Methods
A conjoint analysis was conducted among 750 participants from 7 European countries who were allergic to pollen (n = 700) or Hymenoptera venom (n = 50) and had not previously received AIT. Participants were asked to choose between hypothetical AIT products with different attributes, including product type, initial up-dosing posology, potential future risks, and side effects. The relative importance of each attribute was calculated, and sensitivity analyses were performed to assess the impact of specific attribute levels on patient preference.
Results
Potential future risk is the attribute with the strongest impact on the importance score for patient preference in both pollen (44%) and venom (41%) allergic patients, followed by side effects (24% for pollen and 35% for venom allergy). Product type was less important, with a 22% importance score in both populations, and dosing schedules were not important at all, with a 2% importance score for pollen and an 11% importance score for venom-allergic patients. Accumulation of foreign material/substance in the body had the largest negative impact on patient preference, with drops of −24.7% (pollen) and −23.6% (venom), respectively.
Conclusions
Understanding patient preferences is essential for optimizing the design and delivery of AIT. Different side effects and risk profiles of AIT products can influence patient treatment acceptance the most, and healthcare professionals may not always be aware of it. Future research should focus on developing AIT products that align with patient preferences with simultaneously very high effectiveness to improve adherence and treatment outcomes.
{"title":"Patient preference in allergen immunotherapy - Understanding the patient's view","authors":"Sven Becker MD , Martin Feindor MD , Anke Graessel PhD , Isabel Fernández de Alba MD , Katrin Birkholz PhD , Jennifer Raab PhD , Filippo Fassio MD , Dolores Hernandez MD , Neil Valentine Mr. , Robin Abro Mr. , Oliver Fuchs MD , Simon Blank PhD , Markus Ollert MD , David Gonzalez-de-Olano MD , Ludger Klimek MD , Erika Jensen-Jarolim MD , Peter Schmid-Grendelmeier MD , Gerald Hofer PhD , Matthias F. Kramer MD","doi":"10.1016/j.waojou.2025.101154","DOIUrl":"10.1016/j.waojou.2025.101154","url":null,"abstract":"<div><h3>Background</h3><div>Allergen Immunotherapy (AIT) is an effective treatment for patients with pollen, house dust mite, or venom allergy, but treatment adherence can be challenging. Patient preferences play a crucial role in acceptance and adherence to AIT, but little is known about these preferences. This study aimed to understand patient preferences for AIT and how these preferences influence treatment acceptance.</div></div><div><h3>Methods</h3><div>A conjoint analysis was conducted among 750 participants from 7 European countries who were allergic to pollen (n = 700) or Hymenoptera venom (n = 50) and had not previously received AIT. Participants were asked to choose between hypothetical AIT products with different attributes, including product type, initial up-dosing posology, potential future risks, and side effects. The relative importance of each attribute was calculated, and sensitivity analyses were performed to assess the impact of specific attribute levels on patient preference.</div></div><div><h3>Results</h3><div>Potential future risk is the attribute with the strongest impact on the importance score for patient preference in both pollen (44%) and venom (41%) allergic patients, followed by side effects (24% for pollen and 35% for venom allergy). Product type was less important, with a 22% importance score in both populations, and dosing schedules were not important at all, with a 2% importance score for pollen and an 11% importance score for venom-allergic patients. Accumulation of foreign material/substance in the body had the largest negative impact on patient preference, with drops of −24.7% (pollen) and −23.6% (venom), respectively.</div></div><div><h3>Conclusions</h3><div>Understanding patient preferences is essential for optimizing the design and delivery of AIT. Different side effects and risk profiles of AIT products can influence patient treatment acceptance the most, and healthcare professionals may not always be aware of it. Future research should focus on developing AIT products that align with patient preferences with simultaneously very high effectiveness to improve adherence and treatment outcomes.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101154"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101131
Kazufumi Takada MD, PhD , Maho Suzukawa MD, PhD , Hiroyuki Tashimo MD, PhD , Nobuharu Ohshima MD, PhD , Masaki Ishii MD, PhD , Ken Ohta MD, PhD , the NHOM-Asthma study group
Background
Elderly asthma (EA) and non-elderly asthma (NEA) have been shown to differ greatly. The aim of this study was therefore to identify any differences in the abilities of commonly used asthma questionnaires to predict asthma outcomes in patients with EA and those with NEA, and to further determine the questions that are important for outcome prediction.
Methods
This study analyzed data from the NHOM-Asthma study, a nationwide asthma registry in Japan which included 1014 patients with EA (aged ≥65 years) and 842 with NEA (aged <65 years). The correlations between total scores or individual items of the Asthma Control Questionnaire 6 (ACQ6), Asthma Quality of Life Questionnaire (AQLQ), and Asthma Starts with Knowledge 20, and asthma-related outcomes (unscheduled hospital visits, acute exacerbations, admissions within 1 year, and pulmonary function test results) were analyzed.
Results
Worse baseline ACQ6 and AQLQ scores were significantly correlated with worse asthma-related outcomes in patients with NEA. In contrast, in patients with EA, these scores and the individual question items showed only a weak or no correlation with asthma-related outcomes. Instead, specific questions related to wheezing, nocturnal symptoms, nasal symptoms, and activity limitations were found to be closely associated with asthma-related outcomes in patients with EA. Moreover, the oscillometry data may better reflect the severity of asthma symptoms and activity limitations, as assessed by questionnaires, than spirometry data, including the forced expiratory volume in 1 sec, in patients with EA.
Conclusions
Commonly used asthma questionnaires may not be suitable for predicting outcomes in patients with EA. However, specific questions addressing factors such as wheezing, nocturnal symptoms, nasal issues, and activity limitations may serve as reliable indicators of asthma-related outcomes in these patients.
{"title":"Differences in the efficacies of commonly used asthma questionnaires for predicting asthma-related outcomes among elderly and non-elderly patients in Japan","authors":"Kazufumi Takada MD, PhD , Maho Suzukawa MD, PhD , Hiroyuki Tashimo MD, PhD , Nobuharu Ohshima MD, PhD , Masaki Ishii MD, PhD , Ken Ohta MD, PhD , the NHOM-Asthma study group","doi":"10.1016/j.waojou.2025.101131","DOIUrl":"10.1016/j.waojou.2025.101131","url":null,"abstract":"<div><h3>Background</h3><div>Elderly asthma (EA) and non-elderly asthma (NEA) have been shown to differ greatly. The aim of this study was therefore to identify any differences in the abilities of commonly used asthma questionnaires to predict asthma outcomes in patients with EA and those with NEA, and to further determine the questions that are important for outcome prediction.</div></div><div><h3>Methods</h3><div>This study analyzed data from the NHOM-Asthma study, a nationwide asthma registry in Japan which included 1014 patients with EA (aged ≥65 years) and 842 with NEA (aged <65 years). The correlations between total scores or individual items of the Asthma Control Questionnaire 6 (ACQ6), Asthma Quality of Life Questionnaire (AQLQ), and Asthma Starts with Knowledge 20, and asthma-related outcomes (unscheduled hospital visits, acute exacerbations, admissions within 1 year, and pulmonary function test results) were analyzed.</div></div><div><h3>Results</h3><div>Worse baseline ACQ6 and AQLQ scores were significantly correlated with worse asthma-related outcomes in patients with NEA. In contrast, in patients with EA, these scores and the individual question items showed only a weak or no correlation with asthma-related outcomes. Instead, specific questions related to wheezing, nocturnal symptoms, nasal symptoms, and activity limitations were found to be closely associated with asthma-related outcomes in patients with EA. Moreover, the oscillometry data may better reflect the severity of asthma symptoms and activity limitations, as assessed by questionnaires, than spirometry data, including the forced expiratory volume in 1 sec, in patients with EA.</div></div><div><h3>Conclusions</h3><div>Commonly used asthma questionnaires may not be suitable for predicting outcomes in patients with EA. However, specific questions addressing factors such as wheezing, nocturnal symptoms, nasal issues, and activity limitations may serve as reliable indicators of asthma-related outcomes in these patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101131"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.waojou.2025.101149
Luciana Kase Tanno MD, PhD , Pham Thao Van Luong MD, MSc , Megane Dieval MSc , Caroline Dunoyer PhD , Emma Di Meglio MSc , Florent Fuchs MD, PhD , Nicolas Molinari PhD , Isabella Annesi-Maesano MD, PhD , Pascal Demoly MD, PhD
Background
Anaphylaxis during pregnancy implies a risk to both mothers and newborns. However, limited data are available. Therefore, our aim is to explore patterns of hospital admissions diagnosed with anaphylaxis in pregnant women in France from 2012 to 2021, using a national hospital billing database and to evaluate potential determinants, trends and recurrences.
Methods
Descriptive study using data from the French Program for the Medicalization of Information Systems, from 2012 to 2021. We included all patients hospitalized for anaphylaxis using International Classification of Diseases (ICD)-10 codes listed as a primary diagnosis. Two groups of patients were included: pregnant (PW) and non-pregnant women (NPW), adjusted by age. Severe anaphylaxis (SA) was defined based on the need of admissions in intensive care units. Sankey graphics were employed to visualize data related to recurrences.
Results
During a nine-year study period, 37,962 female patients had 42,399 admissions due to anaphylaxis for all causes. We evaluated data from 734 admissions for anaphylaxis experienced by 653 PW. In both groups 65% of cases were unspecified anaphylaxis, with high number of recurrences. PW experienced higher proportion of SA (8.7%, 95%CI [6.8%, 11.1%]) and recurrences (1.51, 95%CI [1.3, 1,7]), compared with NPW. Most of SA in PW was triggered by drugs (23%, 95%CI [22.3%, 23.6%]). Different from NPW, no seasonal trend was observed in the PW group. From all 670 PW who experienced non-SA, 0.33% (95% CI 0.09–1.2) evolved with SA, and 0.92% (95% CI 0.42–1.99) were admitted for different etiologies in forthcoming admissions.
Conclusion
Beyond providing a snapshot of characteristics of anaphylaxis during pregnancy in France, we were able to explore trends and recurrence of anaphylaxis in this population. Although further research is needed in the field, we strongly believe that the data presented contributed as a starting point of public health advancements to ensure quality of care of patients suffering from anaphylaxis.
背景：怀孕期间的过敏反应对母亲和新生儿都有风险。然而，可用的数据有限。因此，我们的目的是利用国家医院计费数据库，探索2012年至2021年法国孕妇诊断为过敏反应的住院模式，并评估潜在的决定因素、趋势和复发。方法采用2012 - 2021年法国信息系统医疗化项目的数据进行描述性研究。我们纳入了所有使用国际疾病分类(ICD)-10代码作为主要诊断的住院过敏反应患者。患者分为两组：孕妇（PW）和非孕妇（NPW），按年龄调整。严重过敏反应（SA）是根据重症监护病房入院的需要来定义的。采用Sankey图形将与递归相关的数据可视化。结果在9年的研究期间，37,962名女性患者因各种原因的过敏反应而入院。我们评估了653名PW患者因过敏反应入院的734名患者的数据。在两组中，65%的病例为未明确的过敏反应，复发率高。与NPW相比，PW有更高的SA发生率（8.7%,95%CI[6.8%, 11.1%]）和复发率（1.51%,95%CI[1.3, 1,7]）。PW中SA多由药物引发（23%,95%CI[22.3%, 23.6%]）。与NPW不同，PW组无季节性变化趋势。在所有670例非SA患者中，0.33% （95% CI 0.09-1.2）随SA发展，0.92% （95% CI 0.42-1.99）因不同病因入院。结论：除了提供法国妊娠期过敏反应特征的快照外，我们还能够探索这一人群中过敏反应的趋势和复发。虽然该领域还需要进一步的研究，但我们坚信，所提供的数据有助于作为公共卫生进步的起点，以确保过敏反应患者的护理质量。
{"title":"Anaphylaxis and pregnancy: Epidemiology, elicitors, and recurrences","authors":"Luciana Kase Tanno MD, PhD , Pham Thao Van Luong MD, MSc , Megane Dieval MSc , Caroline Dunoyer PhD , Emma Di Meglio MSc , Florent Fuchs MD, PhD , Nicolas Molinari PhD , Isabella Annesi-Maesano MD, PhD , Pascal Demoly MD, PhD","doi":"10.1016/j.waojou.2025.101149","DOIUrl":"10.1016/j.waojou.2025.101149","url":null,"abstract":"<div><h3>Background</h3><div>Anaphylaxis during pregnancy implies a risk to both mothers and newborns. However, limited data are available. Therefore, our aim is to explore patterns of hospital admissions diagnosed with anaphylaxis in pregnant women in France from 2012 to 2021, using a national hospital billing database and to evaluate potential determinants, trends and recurrences.</div></div><div><h3>Methods</h3><div>Descriptive study using data from the French Program for the Medicalization of Information Systems, from 2012 to 2021. We included all patients hospitalized for anaphylaxis using International Classification of Diseases (ICD)-10 codes listed as a primary diagnosis. Two groups of patients were included: pregnant (PW) and non-pregnant women (NPW), adjusted by age. Severe anaphylaxis (SA) was defined based on the need of admissions in intensive care units. Sankey graphics were employed to visualize data related to recurrences.</div></div><div><h3>Results</h3><div>During a nine-year study period, 37,962 female patients had 42,399 admissions due to anaphylaxis for all causes. We evaluated data from 734 admissions for anaphylaxis experienced by 653 PW. In both groups 65% of cases were unspecified anaphylaxis, with high number of recurrences. PW experienced higher proportion of SA (8.7%, 95%CI [6.8%, 11.1%]) and recurrences (1.51, 95%CI [1.3, 1,7]), compared with NPW. Most of SA in PW was triggered by drugs (23%, 95%CI [22.3%, 23.6%]). Different from NPW, no seasonal trend was observed in the PW group. From all 670 PW who experienced non-SA, 0.33% (95% CI 0.09–1.2) evolved with SA, and 0.92% (95% CI 0.42–1.99) were admitted for different etiologies in forthcoming admissions.</div></div><div><h3>Conclusion</h3><div>Beyond providing a snapshot of characteristics of anaphylaxis during pregnancy in France, we were able to explore trends and recurrence of anaphylaxis in this population. Although further research is needed in the field, we strongly believe that the data presented contributed as a starting point of public health advancements to ensure quality of care of patients suffering from anaphylaxis.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101149"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.waojou.2025.101130
Andrés Noyola-Pérez MD , Sandra Nora Gonzalez-Diaz MD, PhD , Carlos Macouzet-Sanchez MD, PhD , Alejandra Macías-Weinnmann MD , Rosa I. Guzmán-Avilán MD, PhD , Cindy E. de Lira-Quezada MD, PhD , Ana K. Chavez-Ruiz MD , Mario Morais-Almeida MD , Byran Martin MD , Ignacio J. Ansotegui MD, PhD , Mariana Castillo-Rubio MD
Introduction
Global disparities in scientific research disproportionately favor high-income countries (HICs), limiting contributions from low- and middle-income countries (LMICs). In allergology, this inequity restricts diverse perspectives and constrains advancements in addressing allergic diseases, which disproportionately affects underserved populations.
Methods
This study analyzed the contributions of 41 allergy journals listed in the 2024 Journal Citation Reports. Data on publication volume, citation impact, article processing charges (APCs), and editorial board representation were collected. Countries were classified as HICs or LMICs based on World Bank rankings. Descriptive statistics and comparative analyses were used to evaluate the disparities between HICs and LMICs.
Results
LMICs accounted for only 18.6% of the total publications, compared to a median of 85% from HICs, and only 1 journal included a low-income country among its top contributors. Journals received contributions from a median of 8 HICs versus 2 LMICs. APCs presented a median cost of 3090 USD, posing a significant financial barrier. Geographic alignment was observed between editorial boards and contributing countries, further limiting LMIC representation.
Conclusion
Systemic barriers, including high APCs numbers and underrepresentation on editorial boards, limit the contribution in global allergology. Addressing these disparities requires reducing financial obstacles, expanding capacity-building initiatives, and ensuring equitable editorial representation. Creating inclusive research ecosystems can enhance global knowledge dissemination and improve outcomes for populations disproportionately affected by allergic diseases.
{"title":"Unequal contributions in global allergy research: A comparative study of high-, low-, and middle-income countries","authors":"Andrés Noyola-Pérez MD , Sandra Nora Gonzalez-Diaz MD, PhD , Carlos Macouzet-Sanchez MD, PhD , Alejandra Macías-Weinnmann MD , Rosa I. Guzmán-Avilán MD, PhD , Cindy E. de Lira-Quezada MD, PhD , Ana K. Chavez-Ruiz MD , Mario Morais-Almeida MD , Byran Martin MD , Ignacio J. Ansotegui MD, PhD , Mariana Castillo-Rubio MD","doi":"10.1016/j.waojou.2025.101130","DOIUrl":"10.1016/j.waojou.2025.101130","url":null,"abstract":"<div><h3>Introduction</h3><div>Global disparities in scientific research disproportionately favor high-income countries (HICs), limiting contributions from low- and middle-income countries (LMICs). In allergology, this inequity restricts diverse perspectives and constrains advancements in addressing allergic diseases, which disproportionately affects underserved populations.</div></div><div><h3>Methods</h3><div>This study analyzed the contributions of 41 allergy journals listed in the 2024 <em>Journal Citation Reports</em>. Data on publication volume, citation impact, article processing charges (APCs), and editorial board representation were collected. Countries were classified as HICs or LMICs based on World Bank rankings. Descriptive statistics and comparative analyses were used to evaluate the disparities between HICs and LMICs.</div></div><div><h3>Results</h3><div>LMICs accounted for only 18.6% of the total publications, compared to a median of 85% from HICs, and only 1 journal included a low-income country among its top contributors. Journals received contributions from a median of 8 HICs versus 2 LMICs. APCs presented a median cost of 3090 USD, posing a significant financial barrier. Geographic alignment was observed between editorial boards and contributing countries, further limiting LMIC representation.</div></div><div><h3>Conclusion</h3><div>Systemic barriers, including high APCs numbers and underrepresentation on editorial boards, limit the contribution in global allergology. Addressing these disparities requires reducing financial obstacles, expanding capacity-building initiatives, and ensuring equitable editorial representation. Creating inclusive research ecosystems can enhance global knowledge dissemination and improve outcomes for populations disproportionately affected by allergic diseases.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 11","pages":"Article 101130"},"PeriodicalIF":4.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145425356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号